APA (7th ed.) Citation

Papachristofilou, A., Hipp, M. M., Klinkhardt, U., Früh, M., Sebastian, M., Weiss, C., . . . Zippelius, A. (2019). Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849(CV9202), combined with local radiation treatment in patients with stage IVnon-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 7(1), . https://doi.org/10.1186/s40425-019-0520-5

Chicago Style (17th ed.) Citation

Papachristofilou, Alexandros, et al. "Phase Ib Evaluation of a Self-adjuvanted Protamine Formulated MRNA-based Active Cancer Immunotherapy, BI1361849(CV9202), Combined with Local Radiation Treatment in Patients with Stage IVnon-small Cell Lung Cancer." Journal for ImmunoTherapy of Cancer 7, no. 1 (2019). https://doi.org/10.1186/s40425-019-0520-5.

MLA (9th ed.) Citation

Papachristofilou, Alexandros, et al. "Phase Ib Evaluation of a Self-adjuvanted Protamine Formulated MRNA-based Active Cancer Immunotherapy, BI1361849(CV9202), Combined with Local Radiation Treatment in Patients with Stage IVnon-small Cell Lung Cancer." Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 2019, https://doi.org/10.1186/s40425-019-0520-5.